[THE INVESTOR] Korean pharmaceutical firm Medipost has been granted a US patent for its cell therapeutic technology used in its osteoarthritis treatment solution Cartistem, the company’s spokesperson said on June 29.
The mechanism alleviates knee cartilage pains with mesenchymal stem cells extracted from allogeneic umbilical cord blood.
 |
Medipost's osteoarthritis treatment solution Cartistem |
Medipost already holds US patents for its two other cell-based technologies that act as bases for treatment of Alzheimer’s disease and Bronchopulmonary dysplasia in premature infants.
By Jung Min-kyung (
mkj1105@heraldcorp.com)
